Drug intelligence / Profile preview

dihydrocodeine tartrate + dl-methylephedrine hydrochloride + chlorpheniramine maleate

Development stage
Unknown
Lead developer
Kyorin Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

A **combination drug** containing dihydrocodeine tartrate (an opioid analgesic and antitussive), dl-methylephedrine hydrochloride (a sympathomimetic bronchodilator), and chlorpheniramine maleate (a first-generation antihistamine)[1][3][6]. - **Mechanism of action**: - Dihydrocodeine acts on the mu-opioid receptor as an agonist, suppressing cough and providing analgesia[5]. - dl-Methylephedrine stimulates adrenergic receptors, relaxing airway smooth muscle to facilitate bronchodilation. - Chlorpheniramine acts as an antagonist at the histamine H1 receptor, reducing allergic symptoms and cough reflex[1][2]. - It is used primarily as an **antitussive** for symptomatic relief of cough related to acute and chronic respiratory diseases, including acute bronchitis, chronic bronchitis, cold/upper respiratory inflammation, pneumonia, and pulmonary tuberculosis[1][4][6]. - This product is approved and marketed in Japan and other countries as a **cough suppressant and cold remedy**[1][4][6].

Brand names
Lightgen Combination SyrupHuscode Combination TabletsCHLOPHEDRIN SCodaewon Forte Syr.
Other names
dihydrocodeine phosphate + dl-methylephedrine hydrochloride + chlorpheniramine maleate
02

Targets

HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on dihydrocodeine tartrate + dl-methylephedrine hydrochloride + chlorpheniramine maleate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dihydrocodeine tartrate + dl-methylephedrine hydrochloride + chlorpheniramine maleate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call